Teva Pharmaceutical Industries

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: United States, Europe, and International Markets. The United States segment focuses on therapeutic area of central nervous system (CNS) portfolio, and is involved in the distribution business of generic, biosimilar and medicines, and over-the-counter (OTC) pharmaceutical products from the firm and third-party manufacturers to independent retail pharmacies, pharmacy retail chains, hospitals, and physician offices in the United States. The Europe segment offers OTC portfolio including SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brands in European Union, the United Kingdom, and certain other European countries. The International Markets segment provides its products to countries such as Canada, Israel, Russia, Latin America, and Japan. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Founded

1901

CEO

Mr. Richard D. Francis

Employees

33,950

Headquarters

Tel Aviv, Tel Aviv, Israel

Fiscal year end

12-31

Website

tevapharm.com

Company profile

Exchange

US

Symbol

TEVA

Market-cap rank

#471

Listing date

1970-01-01

Market cap

45.70B

Float cap

42.69B

Shares out

1.17B

Float shares

1.09B

Sectors & themes

Browse all sectors & themes